Can you recall the year keytruda was first approved by the fda for cancer therapy?

When was Keytruda first approved by the FDA?

The FDA approved Keytruda (pembrolizumab) in September 2014 for unresectable or metastatic melanoma. [1]

How does the 2014 approval differ from later Keytruda indications?

The first label covered only advanced melanoma. Subsequent approvals expanded the drug to non-small cell lung cancer, head and neck cancer, and over twenty additional tumor types or biomarker-driven uses. [1]

When did Keytruda patents expire or face challenges?

Key patents covering the antibody sequence and dosing methods begin to expire in 2028, with some formulation and combination patents extending later. Multiple companies have filed challenges or developed biosimilar candidates ahead of those dates. [2]

How does Keytruda compare with Opdivo in timing and scope?

Opdivo received its first FDA approval in December 2014, three months after Keytruda. Both drugs block PD-1, but Keytruda secured earlier single-agent approval in melanoma and has maintained a broader set of approved indications. [1]

What side effects are patients most concerned about?

Common reports center on immune-related reactions such as colitis, pneumonitis, hepatitis, and endocrinopathies. These effects can appear weeks to months after starting treatment and sometimes require steroids or treatment interruption. [3]

[1] https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda
[2] https://www.drugpatentwatch.com/drug/pembrolizumab
[3] https://www.keytruda.com/side-effects/